Catherine Fayolle
  • Immune Regulation and Vaccinology, INSERM U1041 , Equipe Labellisée Ligue Contre le Cancer, Pasteur Institute, France
研究方向
  • Immunology
个人信息

Education

Ph.D in Molecular and Cellular Pharmacology, University of Paris VI, 1984

Current position

Research engineer, Department of Immunology, Pasteur Institute, Paris, France

Publications (since 2005)

  1. Chaoul, N., Fayolle, C., Desrues, B., Oberkampf, M., Tang, A., Ladant, D. and Leclerc, C. (2015). Rapamycin Impairs Antitumor CD8+ T-cell Responses and Vaccine-Induced Tumor Eradication. Cancer Res 75(16): 3279-3291.
  2. Dadaglio, G., Fayolle, C., Zhang, X., Ryffel, B., Oberkampf, M., Felix, T., Hervas-Stubbs, S., Osicka, R., Sebo, P., Ladant, D. and Leclerc, C. (2014). Antigen targeting to CD11b+ dendritic cells in association with TLR4/TRIF signaling promotes strong CD8+ T cell responses. J Immunol 193(4): 1787-1798.
  3. Fiser, R., Masin, J., Bumba, L., Pospisilova, E., Fayolle, C., Basler, M., Sadilkova, L., Adkins, I., Kamanova, J., Cerny, J., Konopasek, I., Osicka, R., Leclerc, C. and Sebo, P. (2012). Calcium influx rescues adenylate cyclase-hemolysin from rapid cell membrane removal and enables phagocyte permeabilization by toxin pores. PLoS Pathog 8(4): e1002580.
  4. Rudilla, F., Fayolle, C., Casares, N., Durantez, M., Arribillaga, L., Lozano, T., Villanueva, L., Pio, R., Sarobe, P., Leclerc, C., Prieto, J. and Lasarte, J. J. (2012). Combination of a TLR4 ligand and anaphylatoxin C5a for the induction of antigen-specific cytotoxic T cell responses. Vaccine 30(18): 2848-2858.
  5. Osickova, A., Masin, J., Fayolle, C., Krusek, J., Basler, M., Pospisilova, E., Leclerc, C., Osicka, R. and Sebo, P. (2010). Adenylate cyclase toxin translocates across target cell membrane without forming a pore. Mol Microbiol 75(6): 1550-1562.
  6. Fayolle, C., Davi, M., Dong, H., Ritzel, D., Le Page, A., Knipping, F., Majlessi, L., Ladant, D. and Leclerc, C. (2010). Induction of anti-Tat neutralizing antibodies by the CyaA vector targeting dendritic cells: influence of the insertion site and of the delivery of multicopies of the dominant Tat B-cell epitope. Vaccine 28(42): 6930-6941.
  7. Durantez, M., Fayolle, C., Casares, N., Belsue, V., Riezu-Boj, J. I., Sarobe, P., Prieto, J., Borras-Cuesta, F., Leclerc, C. and Lasarte, J. J. (2010). Tumor therapy in mice by using a tumor antigen linked to modulin peptides from Staphylococcus epidermidis. Vaccine 28(44): 7146-7154.
  8. Mascarell, L., Bauche, C., Fayolle, C., Diop, O. M., Dupuy, M., Nougarede, N., Perraut, R., Ladant, D. and Leclerc, C. (2006). Delivery of the HIV-1 Tat protein to dendritic cells by the CyaA vector induces specific Th1 responses and high affinity neutralizing antibodies in non human primates. Vaccine 24(17): 3490-3499.
  9. Mascarell, L., Fayolle, C., Bauche, C., Ladant, D. and Leclerc, C. (2005). Induction of neutralizing antibodies and Th1-polarized and CD4-independent CD8+ T-cell responses following delivery of human immunodeficiency virus type 1 Tat protein by recombinant adenylate cyclase of Bordetella pertussis. J Virol 79(15): 9872-9884.